Laddar...
A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much‐awaited out‐of‐class alternatives for patients who ha...
Sparad:
| I publikationen: | JGH Open |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Wiley Publishing Asia Pty Ltd
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6207060/ https://ncbi.nlm.nih.gov/pubmed/30483594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12065 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|